Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
25.97
-0.49 (-1.85%)
Jul 24, 2025, 4:00 PM - Market closed

Company Description

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer.

Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.

Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates.

The company was incorporated in 2017 and is headquartered in San Diego, California.

Janux Therapeutics, Inc.
Janux Therapeutics logo
CountryUnited States
Founded2017
IPO DateJun 11, 2021
IndustryBiotechnology
SectorHealthcare
Employees81
CEODavid Campbell

Contact Details

Address:
10955 Vista Sorrento Parkway, Suite 200
San Diego, California 92130
United States
Phone858 751 4493
Websitejanuxrx.com

Stock Details

Ticker SymbolJANX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$17.00
CIK Code0001817713
CUSIP Number47103J105
ISIN NumberUS47103J1051
Employer ID82-2289112
SIC Code2834

Key Executives

NamePosition
Dr. David Alan Campbell Ph.D.President, Chief Executive Officer and Director
Dr. Thomas Diraimondo Ph.D.Chief Scientific Officer
Byron Robinson J.D., Ph.D.Chief Strategy Officer
Matt WhitmireVice President of Finance
Maria DobekPrincipal Accounting Officer and Vice President of Accounting
Charles M. WinterChief Technical Officer
James PenningtonGeneral Counsel and Corporate Secretary
Janeen DoyleChief Corporate and Business Development Officer
Andy Hollman MeyerChief Business Officer
Dr. Zachariah McIver D.O., Ph.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Jul 17, 2025SCHEDULE 13GFiling
Jun 13, 20258-KCurrent Report
May 14, 2025SCHEDULE 13G/AFiling
May 8, 202510-QQuarterly Report
May 8, 20258-KCurrent Report
May 1, 2025144Filing
Apr 25, 2025ARSFiling
Apr 25, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2025DEF 14AOther definitive proxy statements
Apr 21, 2025144Filing